Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax-Reference-Cited by-同舟云学术

Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax

Published:2023-02-09 Issue:4 Volume:98 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Candoni Anna¹^ORCID,Lazzarotto Davide²^ORCID,Papayannidis Cristina³,Piccini Matteo⁴,Nadali Giampaolo⁵,Dargenio Michelina⁶^ORCID,Riva Marta⁷,Fracchiolla Nicola⁸,Mellillo Lorella⁹,Dragonetti Giulia¹⁰,Del Principe Maria Ilaria¹¹^ORCID,Cattaneo Chiara¹²,Stulle Manuela¹³,Pasciolla Crescenza¹⁴,De Marchi Roberta¹⁵,Delia Mario¹⁶^ORCID,Tisi Maria Chiara¹⁷,Bonuomo Valentina⁵^ORCID,Sciumè Mariarita⁷^ORCID,Spadea Antonio¹⁸,Sartor Chiara³,Griguolo Davide¹³,Buzzatti Elisa¹¹^ORCID,Basilico Claudia Maria¹⁹,Sarlo Chiara²⁰,Piccioni Anna Lina²¹,Cerqui Elisa¹²,Lessi Federica²²,Olivieri Attilio²³,Fanin Renato²,Luppi Mario¹,Pagano Livio¹⁰^ORCID

Affiliation:

1. Section of Hematology, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena Università di Modena e Reggio Emilia Modena Italy

2. Division of Hematology and Stem Cell Transplantation, ASUFC University of Udine Udine Italy

3. Institute of Hematology and Medical Oncology "L. and A. Seragnoli" University of Bologna Bologna Italy

4. Division of Hematology Azienda Ospedaliero‐Universitaria Careggi Florence Italy

5. Division of Hematology AOUI, Policlinico GB Rossi Verona Italy

6. Division of Hematology Ospedale Vito Fazzi Lecc Italy

7. Dipartimento di Ematologia ed Oncologia Niguarda Cancer Center ASST Grande Ospedale Metropolitano Milan Italy

8. U.O. Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan Milan Italy

9. Division of Hematology Foggia and IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo Italy

10. Division of Hematology, Polo Onco‐Ematologico, Fondazione Policlinico A. Gemelli‐IRCCS Università Cattolica del Sacro Cuore Rome Italy

11. Hematology Fondazione Policlinico Tor Vergata Rome Italy

12. Section of Hematology Spedali Civili Brescia Italy

13. Division of Hematology ASUGI Trieste Italy

14. Haematology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy

15. Onco Hematology, Department of Oncology Veneto Institute of Oncology IOV, IRCCS Padova Italy

16. Hematology and Bone Marrow Transplantation Unit Azienda Ospedaliero‐Universitaria Consorziale Policlinico‐University of Bari Bari Italy

17. Cell Therapy and Hematology San Bortolo Hospital, Vicenza. 7 U.O. Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan Milan Italy

18. Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy

19. Division of Hematology ASST Sette Laghi, Ospedale Circolo e Fondazione Macchi Varese Italy

20. Hematology and Stem Cell Transplantation Unit University Campus Bio‐Medico Rome Italy

21. Dipartimento di Ematologia Azienda Ospedaliera San Giovanni Addolorata Rome Italy

22. Hematology Unit, Department of Medicine (DIMED) Azienda Ospedaliera Universitaria di Padova Padova Italy

23. Division of Hematology Azienda Ospedaliero‐Universitaria Ospedali Riuniti di Ancona Ancona Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26846

Reference6 articles.

1. How I treat acute myeloid leukemia in the era of new drugs

2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

3. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

4. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

5. Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax;Hematological Oncology;2024-09

2. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

3. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia;The Lancet Haematology;2024-04

4. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients;Leukemia;2024-03-27

5. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda;Cancers;2024-01-16